Mark Fineman

Mark Fineman joined Elcelyx as Vice President of Development and has been Senior Vice President, R&D since early 2013. He was formerly Senior Director, Medical Development and Strategic Relations at Amylin Pharmaceuticals. During his 21year tenure at Amylin, he held various leadership positions in Medical Development, Clinical Pharmacology/Translational Medicine, and Medical Affairs. Dr. Fineman was the Development Core Team leader for Byetta® (exenatide for treatment of type 2 diabetes) through US and European market authorization. He was also responsible for Clinical and Regulatory Affairs at Psylin Neurosciences, Inc., a virtual biotech company spun out of Amylin Pharmaceuticals, Inc. and PsychoGenics Inc. to evaluate peptide hormones for the treatment of psychiatric disorders. Dr. Fineman has authored over 40 original publications and is an inventor on several patents.

Dr. Fineman graduated from California Polytechnic State University, San Luis Obispo with a B.S. in Microbiology (Clinical Chemistry emphasis) and received Master of Science and Master of Advanced Studies degrees in Molecular Pathology and Clinical Research from the University of California, San Diego. Dr. Fineman received a Ph.D. in medicine at Vrije Universiteit Amsterdam.